Rambeck B, May T
Ther Drug Monit. 1984;6(2):164-72. doi: 10.1097/00007691-198406000-00006.
The ratio of the concentration of the phenytoin metabolite hydroxyphenyl phenylhydantoin (HPPH) to the creatinine concentration in morning urine samples was used as an index of compliance in adult epileptic patients on phenytoin therapy. For this purpose, the phenytoin dose was estimated from the urinary HPPH/creatinine ratio with the help of a regression equation that took into consideration body weight, height, age, and sex. A high correlation (r = 0.927 for men and r = 0.954 for women) between the prescribed and estimated dose was found for a reference group (127 hospitalized patients on supervised drug regimen). Compliance was judged from the discrepancy between the prescribed and the estimated dose for 45 patients immediately after their admittance to an epilepsy clinic, as well as for 98 outpatients, who had been treated by neurologists. Noncompliance was suspected in 6.7% of patients admitted to the clinic, as well as in 28.6% of the outpatients.
在接受苯妥英治疗的成年癫痫患者中，早晨尿液样本中苯妥英代谢物羟苯基苯乙内酰脲（HPPH）的浓度与肌酐浓度之比被用作依从性指标。为此，借助一个考虑了体重、身高、年龄和性别的回归方程，根据尿中HPPH/肌酐比值估算苯妥英剂量。在一个参考组（127名接受监督药物治疗方案的住院患者）中，发现规定剂量与估算剂量之间存在高度相关性（男性r = 0.927，女性r = 0.954）。根据45名患者入院后立即在癫痫诊所以及98名接受神经科医生治疗的门诊患者的规定剂量与估算剂量之间的差异来判断依从性。在诊所收治的患者中，有6.7%被怀疑不依从，门诊患者中有28.6%被怀疑不依从。
